Title
Category
Credits
Event date
Cost
Diagnosis and Management of Blastic Plasmacytoid Dendritic Cell Neoplasm
  • Acute Myelogenous Leukemia
  • 0.50 AAPA Category 1 CME credit
  • 0.50 ACPE contact hours
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC contact hours
  • 0.50 Participation
$0.00
Despite the rarity of blastic plasmacytoid dendritic cell neoplasm (BPDCN), it is crucial for the disease to remain in the differential diagnosis of neoplastic and non-neoplastic skin lesions and rashes, including leukemia cutis, as the disease can disseminate rapidly without therapy. The preferred treatment option for BPDCN is the CD123 targeted therapy tagraxofusp ersz. Tagraxofusp-ersz can be associated with potentially life-threatening capillary leak syndrome, and it is crucial to be aware of management strategies if utilizing this agent.
Recorded Presentation from the NCCN Pharmacy Updates: Maintenance Strategies in the Management of Acute Myeloid Leukemia
  • Acute Myelogenous Leukemia
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
Maintenance therapy is an aspect of acute myeloid leukemia (AML) management that currently demonstrates strong promise in efforts to prolong survivability and improve overall survival. Given the forthcoming evidence in this area, it is highly important for health care professionals responsible for the care of patients with AML to be aware of both new treatment standards and emerging research in maintenance therapy options.
Review of Oral Targeted Therapies in Acute Myeloid Leukemia
  • Acute Myelogenous Leukemia
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
$0.00
In recent years, there has been an increased emphasis on molecular and genetic alterations in the classification system of acute myeloid leukemia, and, with this, an increase in the development of targeted therapies. Oral targeted therapies such as FLT3 inhibitors and IDH1/2 inhibitors are being increasingly used in the frontline setting. Oral targeted therapies come with unique and potentially life-threatening toxicities, such as cardiac toxicity with FLT3 inhibitors and differentiation syndrome with IDH1/2 inhibitors.
Archived NCCN Tumor Boards: Acute Myeloid Leukemia: The Importance of Individualized Patient Care
  • Acute Myelogenous Leukemia
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
$0.00
Individualized patient care is highly important in acute myeloid leukemia (AML) therapy to ensure the most effective treatment regimens can be selected for appropriate patients.